Patients on TNFi have no efficacy benefit from TDM

Therapeutic drug monitoring (TDM) doesn’t appear to improve clinical outcomes in patients with rheumatic diseases starting infliximab therapy. Presented at ACR Convergence 2020, the Norwegian Drug Monitoring Trial (NOR-DRUM) is believed to be the first RCT to compare TDM versus a standard approach to dosing in patients with any approved indication for infliximab. Part A ...

Already a member?

Login to keep reading.

© 2021 the limbic